Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hunter Syndrome Treatment Market

Hunter Syndrome Treatment Market Share

Report ID: GMI10514
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Hunter Syndrome Treatment Market Share

The Hunter syndrome treatment industry is characterized by the presence of several established and emerging players that offer a variety of products across the globe. The market players compete based on factors such as product quality, innovation, regulatory compliance, customer service, and pricing strategies.

Hunter Syndrome Treatment Market Companies

Prominent players operating in the Hunter syndrome treatment industry include:

Astellas Pharma Inc.
B.Braun
Baxter International
CHIESI Farmaceutici S.p.A.
Fresenius Kabi
GC Pharma
JCR Pharmaceuticals
Takeda Pharmaceutical Company Limited
Terumo Corporation
Thermo Fisher Scientific

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Hunter syndrome treatment market was valued at USD 845.8 million in 2023 and is anticipated to witness growth at 5.9% CAGR during 2024-2032 driven by the increasing prevalence of hunter syndrome coupled with rising R&D expenditure.

The hospitals segment in the market was valued at USD 492.5 million in 2023 as they offer a range of treatment options, including enzyme replacement therapy (ERT).

North America hunter syndrome treatment market size was valued at USD 403.5 million in 2023 and is predicted to grow at 5.4% CAGR during 2024-2032 driven by the advanced healthcare infrastructure.

Astellas Pharma Inc., B.Braun, Baxter International, CHIESI Farmaceutici S.p.A., Fresenius Kabi, GC Pharma, JCR Pharmaceuticals, Takeda Pharmaceutical Company Limited, Terumo Corporation, and Thermo Fisher Scientific